Hoth Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

• Hoth Therapeutics Inc HOTH.OQ reported a quarterly adjusted loss of 31 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -60 cents. The mean expectation of three analysts for the quarter was for a loss of 34 cents per share. Wall Street expected results to range from -37 cents to -30 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Hoth Therapeutics Inc's reported EPS for the quarter was a loss of 31 cents​.

• The company reported a quarterly loss of $2.13 million.

• Hoth Therapeutics Inc shares had risen by 2.2% this quarter and lost 37.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 20.9% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Hoth Therapeutics Inc is $4.00

This summary was machine generated from LSEG data November 13 at 02:24 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)